Working toward delivering a significantimprovement in the health and quality of lifeto future generations living with XLHED
Information for Professionals – Clinical Trials
Edimer Pharmaceuticals has a recombinant protein (EDI200) that is being developed as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). EDI200 will be evaluated in upcoming clinical trials.
We will provide information on this website as our plans for future clinical trials are updated but you or your patients may also find out more about our clinical trials by visiting http://www.clinicaltrials.gov
XLHED Network
Edimer is committed to developing a treatment for XLHED, and to improving the health and quality of life of future generations living with XLHED. We have created a network for patients, family members and healthcare professionals who would like to stay informed and stay connected to our efforts. Click here to register today.
Stay informed. Stay connected.
Register for the XLHED Network today.
Are you a woman who is a confirmed or suspected carrier of XLHED?
Would you like to be involved in XLHED research? Consider taking this survey www.surveymonkey.com/s/X-CORS
To learn about other studies we are conducting right now visit: clinicaltrials.gov
Edimer Appoints Dan Lynch to Company's Board of Directors
Read more >>
